设为首页 加入收藏

TOP

KADCYLA (trastuzumab emtansine) injection(十)
2014-07-17 15:40:02 来源: 作者: 【 】 浏览:7496次 评论:0

All grades (%)

Grade 3 – 4 (%)
 ND = Not determined

* Nodular Regenerative Hyperplasia and Portal Hypertension occurred in the same patient.

Blood and Lymphatic System Disorders

Neutropenia

6.7

2.0

9.0

4.3
 
Anemia

14.3

4.1

10.5

2.5

Thrombocytopenia

31.2

14.5

3.3

0.4

Cardiac Disorders

Left ventricular dysfunction

1.8

0.2

3.3

0.4

Eye Disorders

Lacrimation increased

3.3

0

2.5

0

Dry eye

3.9

0

3.1

0

Vision blurred

4.5

0

0.8

0

Conjunctivitis

3.9

0

2.3

0

Gastrointestinal Disorders

Dyspepsia

9.2

0

11.5

0.4

Stomatitis

14.1

0.2

32.6

2.5

Dry Mouth

16.7

0

4.9

0.2

Abdominal pain

18.6

0.8

17.6

1.6

Vomiting

19.2

0.8

29.9

4.5

Diarrhea

24.1

1.6

79.7

20.7
 
Constipation

26.5

0.4

11.1

0
 Nausea

39.8

0.8

45.1

2.5

General Disorders and Administration

Peripheral edema

7.1

0

8.2

0.2

Chills

7.6

0

3.1

0

Pyrexia

18.6

0.2

8.4

0.4

Asthenia

17.8

0.4

17.6

1.6

Fatigue

36.3

2.5

28.3

3.5

Hepatobiliary Disorders

Nodular regenerative hyperplasia*

0.4

ND

0

0

Portal hypertension*

0.4

0.2

0

0

Immune System Disorders

Drug hypersensitivity

2.2

0

0.8

0

Injury, Poisoning, and Procedural

Infusion-related reaction

1.4

0

0.2

0

Infections and Infestations

Urinary tract infection

9.4

0.6

3.9

0

Investigations

Blood alkaline phosphatase increased

4.7

0.4

3.7

0.4

Increased transaminases

28.8

8.0

14.3

2.5

Metabolism and Nutrition Disorders
Hypokalemia

10.2

2.7

9.4

4.7

Musculoskeletal and Connective Tissue Disorders
 
Myalgia

14.1

0.6

3.7

0

Arthralgia

19.2

0.6

8.4

0

Musculoskeletal pain

36.1

1.8

30.5

1.4

Nervous System Disorders

Dysgeusia

8.0

0

4.1

0.2

Dizziness

10.2

0.4

10.7

0.2

Peripheral neuropathy

21.2

2.2

13.5

0.2

Headache

28.2

0.8

14.5

0.8

Psychiatric Disorders

Insomnia

12.0

0.4

8.6

0.2

Respiratory, Thoracic, and Mediastinal Disorders

Pneumonitis

1.2

0

0

0

Dyspnea

12.0

0.8

8.0

0.4

Cough

18.2

0.2

13.1

0.2

Epistaxis

22.5

0.2

8.4

0

Skin and Subcutaneous Tissue Disorders

Pruritus

5.5

0.2

9.2

0

Rash

11.6

0

27.5

1.8

Vascular Disorders

Hypertension

5.1

1.2

2.3

0.4
 

Table 7 Selected Laboratory Abnormalities

 Parameter

KADCYLA
(3

以下是“全球医药”详细资料
Tags: 责任编辑:admin
首页 上一页 7 8 9 10 11 12 13 下一页 尾页 10/19/19
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇特立氟胺胶囊TAFINLAR (dabrafeni.. 下一篇NESINA (alogliptin) tablet, fil..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位